Group 1 - The company Ark Health (06086) successfully raised HKD 150 million through a share placement at HKD 3.32 per share, representing approximately 3.26% of the expanded issued share capital as of the announcement date [1] - The net proceeds, approximately HKD 129 million, will be used to accelerate the development of the "AI + chronic disease management" platform, including model development, infrastructure expansion, talent recruitment, data collection, and knowledge base construction [2][3] - The company aims to enhance its services to cover more patients and doctors, leveraging AI technology to transform traditional health service models and improve the efficiency of healthcare resource allocation [2] Group 2 - The share placement received an enthusiastic response from the capital market, indicating strong confidence from professional investors in the company's "familiar doctor-patient" model and its value creation [4] - The company projects a revenue of approximately CNY 3.5 billion for 2025, reflecting a year-on-year growth of about 30%, and expects to achieve a net profit of CNY 7-10 million, marking a transition to full profitability [4] - The "familiar doctor-patient" model establishes high trust relationships, ensuring continuity and adherence in patient management, which is crucial for long-term success in chronic disease management [5] Group 3 - The company is positioned to benefit from the growing chronic disease management market in China, projected to exceed CNY 600 billion by 2030, driven by aging and high prevalence of chronic diseases [5] - The integration of AI technology is expected to enhance the company's service offerings, contributing to the achievement of the "Healthy China 2030" goal and setting a benchmark for high-quality industry development [5]

如果说财务数据是企业健康的体检表，那么方舟健客这份"2025年成绩单"无疑展示了一个强健的体魄。 30%的营收增速，在存量竞争激烈的互联网医疗领域已属难能可贵，而"双重盈利"的达成，则进一步彰 显了其商业模式扎实的盈利基础和可持续的增长潜力。 事实上，在方舟健客的业绩突破获得市场关注前，已有投资机构提前捕捉到其价值信号。 智通财经APP获悉，近年来，中国医疗健康产业正经历一场深刻的范式转变，从粗放式的规模扩张逐渐 迈向精细化的价值深耕。在这一转型的关键节点，方舟健客(06086)以其扎实的财务表现，率先验证了 以"熟人医患"信任关系为核心的慢病服务模式，向市场释放出的强大确定性与增长潜力。 日前，方舟健客发布了2025年正面盈利预告，数据显示，公司预计全年营收达35-35.5亿元，同比增长 约30%。营收规模超越了此前机构预测的35亿港元(约合人民币31.3亿元)。在利润端，继2024年实现经 调整层面盈利后，公司2025年预计实现净利润700-1000万元，正式达成全面盈利。 其业绩的高质量增长，正是以"熟人医患"为基础的商业模式价值的一次集中验证。这不仅为市场重新评 估其内在价值提供了坚实的依据，也有力支 ...

Core Viewpoint - The internet healthcare company Fangzhou Jianke has entered a performance realization phase, achieving significant revenue growth and profitability, indicating a shift towards value-driven development in the chronic disease management sector [1][2]. Financial Performance - In the first half of 2025, Fangzhou Jianke reported revenue of 1.494 billion yuan, with a 28.2% year-on-year increase in online retail pharmacy services revenue [1]. - The company turned a profit with a net profit of 12.5 million yuan, and adjusted net profit reached a record high of 17.6 million yuan, up 16.8% year-on-year [1]. User Engagement and Loyalty - Fangzhou Jianke has cultivated a loyal user base, with a high repurchase rate of 85.4% among paying users, and a registered user count of 52.8 million, with 11.9 million monthly active users [4][5]. - The company’s "familiar doctor-patient" model has led to a strong user loyalty and willingness to pay, which is above industry averages [5]. Market Position and Valuation - Despite its strong performance, Fangzhou Jianke is significantly undervalued compared to competitors like JD Health and Alibaba Health, which have market capitalizations of 200 billion HKD and over 80 billion HKD, respectively, while Fangzhou Jianke's market cap is around 5 billion HKD [1][7]. - Analysts suggest that the potential market value of Fangzhou Jianke could range from 35.7 billion to 47.6 billion HKD based on user engagement metrics, indicating a substantial undervaluation [7]. Competitive Landscape - The company’s business model is likened to Xiaomi's "Mi Fan" model, emphasizing the importance of loyal users and high-frequency interactions as key drivers of growth [5][6]. - Fangzhou Jianke's focus on chronic disease management and its innovative AI-driven healthcare platform positions it well within the competitive landscape of internet healthcare [1][8]. Intangible Assets and Future Potential - The company possesses significant intangible assets, particularly in its medical service capabilities and human capital, which are not yet accurately quantified in market valuations [8]. - The lack of consensus on how to measure the value of healthcare service assets contributes to the current undervaluation of Fangzhou Jianke [7][8].